--- title: "After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH" type: "News" locale: "en" url: "https://longbridge.com/en/news/273029175.md" description: "Several biotech and healthcare stocks saw significant after-hours gains on Friday, influenced by regulatory updates and investor sentiment. Atossa Therapeutics (ATOS) rose 12.98% to $0.69 after receiving Orphan Drug Designation from the FDA. ImmunityBio (IBRX) increased 9.43% to $6.04, with strong trial enrollment. Femasys (FEMY) climbed 10.68% to $0.72 after securing a compliance extension. Foghorn Therapeutics (FHTX) gained 4.02% to $6.26 following a $50 million financing. Daré Bioscience (DARE) and Theravance Biopharma (TBPH) also saw modest gains despite no new announcements." datetime: "2026-01-20T04:22:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273029175.md) - [en](https://longbridge.com/en/news/273029175.md) - [zh-HK](https://longbridge.com/zh-HK/news/273029175.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273029175.md) | [繁體中文](https://longbridge.com/zh-HK/news/273029175.md) # After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH Add as your preferred news source on Google Add Now Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment. Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, up $0.080 after announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The designation marks a significant milestone for the company's pipeline. ImmunityBio, Inc. (IBRX) advanced 9.43% to $6.04, gaining $0.52. The company reported that enrollment in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer has surpassed expectations, with more than 85% of the study population enrolled. Full enrollment is anticipated by the second quarter of 2026, with a biologics license application submission to the FDA targeted by year end 2026. Femasys Inc. (FEMY) climbed 10.68% to $0.72, up $0.070. On January 14, the company disclosed that Nasdaq approved its request for an additional 180-day extension to regain compliance with the minimum $1.00 bid price requirement. Femasys now has until July 13, 2026 to meet the listing standard. Foghorn Therapeutics Inc. (FHTX) gained 4.02% to $6.26, adding $0.24. The company announced the closing of a $50 million registered direct financing at a 30% premium. The offering included common stock, pre-funded warrants, and series warrants priced at multiples of the issue price, with gross proceeds totaling approximately $50 million. Daré Bioscience, Inc. (DARE) edged higher by 1.04% to $1.95, up $0.020. The company did not release any news on Friday, but shares still managed modest after-hours gains. Theravance Biopharma, Inc. (TBPH) gained 5.00% to $21.01, adding $1.00. Similar to Daré, the company had no news on Friday, yet shares advanced in extended trading. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md) - [Foghorn Therapeutics Inc. (FHTX.US)](https://longbridge.com/en/quote/FHTX.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [ImmunityBio, Inc. (IBRX.US)](https://longbridge.com/en/quote/IBRX.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Theravance Biopharma, Inc. (TBPH.US)](https://longbridge.com/en/quote/TBPH.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [Femasys Inc. (FEMY.US)](https://longbridge.com/en/quote/FEMY.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [Daré Bioscience, Inc. (DARE.US)](https://longbridge.com/en/quote/DARE.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [Atossa Therapeutics, Inc. (ATOS.US)](https://longbridge.com/en/quote/ATOS.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Foghorn Narrows Losses, Strengthens Cash Runway, Advances Cancer Pipeline](https://longbridge.com/en/news/278833687.md) - [Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | ACRS Stock News](https://longbridge.com/en/news/279581540.md) - [Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010](https://longbridge.com/en/news/279611034.md) - [Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results](https://longbridge.com/en/news/279269040.md) - [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/en/news/279429425.md)